×
S&P 500   4,144.86 (+2.14%)
DOW   33,097.88 (+1.41%)
QQQ   307.81 (+2.83%)
AAPL   149.10 (+3.70%)
MSFT   271.66 (+2.17%)
FB   194.76 (+1.63%)
GOOGL   2,240.71 (+3.94%)
AMZN   2,282.03 (+2.72%)
TSLA   757.43 (+7.02%)
NVDA   188.12 (+5.38%)
BABA   93.23 (-1.32%)
NIO   16.47 (+2.74%)
AMD   102.11 (+3.40%)
CGC   4.85 (-12.61%)
MU   73.30 (+3.82%)
T   21.25 (-0.33%)
GE   78.40 (+1.80%)
F   13.57 (+3.43%)
DIS   109.32 (+3.51%)
AMC   14.39 (+17.66%)
PFE   53.66 (-0.61%)
PYPL   85.13 (+5.86%)
NFLX   194.45 (+1.59%)
S&P 500   4,144.86 (+2.14%)
DOW   33,097.88 (+1.41%)
QQQ   307.81 (+2.83%)
AAPL   149.10 (+3.70%)
MSFT   271.66 (+2.17%)
FB   194.76 (+1.63%)
GOOGL   2,240.71 (+3.94%)
AMZN   2,282.03 (+2.72%)
TSLA   757.43 (+7.02%)
NVDA   188.12 (+5.38%)
BABA   93.23 (-1.32%)
NIO   16.47 (+2.74%)
AMD   102.11 (+3.40%)
CGC   4.85 (-12.61%)
MU   73.30 (+3.82%)
T   21.25 (-0.33%)
GE   78.40 (+1.80%)
F   13.57 (+3.43%)
DIS   109.32 (+3.51%)
AMC   14.39 (+17.66%)
PFE   53.66 (-0.61%)
PYPL   85.13 (+5.86%)
NFLX   194.45 (+1.59%)
S&P 500   4,144.86 (+2.14%)
DOW   33,097.88 (+1.41%)
QQQ   307.81 (+2.83%)
AAPL   149.10 (+3.70%)
MSFT   271.66 (+2.17%)
FB   194.76 (+1.63%)
GOOGL   2,240.71 (+3.94%)
AMZN   2,282.03 (+2.72%)
TSLA   757.43 (+7.02%)
NVDA   188.12 (+5.38%)
BABA   93.23 (-1.32%)
NIO   16.47 (+2.74%)
AMD   102.11 (+3.40%)
CGC   4.85 (-12.61%)
MU   73.30 (+3.82%)
T   21.25 (-0.33%)
GE   78.40 (+1.80%)
F   13.57 (+3.43%)
DIS   109.32 (+3.51%)
AMC   14.39 (+17.66%)
PFE   53.66 (-0.61%)
PYPL   85.13 (+5.86%)
NFLX   194.45 (+1.59%)
S&P 500   4,144.86 (+2.14%)
DOW   33,097.88 (+1.41%)
QQQ   307.81 (+2.83%)
AAPL   149.10 (+3.70%)
MSFT   271.66 (+2.17%)
FB   194.76 (+1.63%)
GOOGL   2,240.71 (+3.94%)
AMZN   2,282.03 (+2.72%)
TSLA   757.43 (+7.02%)
NVDA   188.12 (+5.38%)
BABA   93.23 (-1.32%)
NIO   16.47 (+2.74%)
AMD   102.11 (+3.40%)
CGC   4.85 (-12.61%)
MU   73.30 (+3.82%)
T   21.25 (-0.33%)
GE   78.40 (+1.80%)
F   13.57 (+3.43%)
DIS   109.32 (+3.51%)
AMC   14.39 (+17.66%)
PFE   53.66 (-0.61%)
PYPL   85.13 (+5.86%)
NFLX   194.45 (+1.59%)
NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$43.11
+1.16 (+2.77%)
(As of 05/27/2022 03:06 PM ET)
Add
Compare
Today's Range
$41.28
▼
$43.24
50-Day Range
$35.07
▼
$59.21
52-Week Range
$27.50
▼
$73.00
Volume
43,110 shs
Average Volume
1.10 million shs
Market Capitalization
$4.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.63
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Apellis Pharmaceuticals logo

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Headlines

May 26, 2022 | americanbankingnews.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $84.00
May 24, 2022 | markets.businessinsider.com
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
May 22, 2022 | americanbankingnews.com
Credit Suisse Group Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $49.00
May 14, 2022 | americanbankingnews.com
Apellis Pharmaceuticals, Inc. to Post Q2 2022 Earnings of ($1.52) Per Share, Oppenheimer Forecasts (NASDAQ:APLS)
May 12, 2022 | finance.yahoo.com
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 9, 2022 | americanbankingnews.com
Apellis Pharmaceuticals (NASDAQ:APLS) Given New $102.00 Price Target at Raymond James
May 5, 2022 | seekingalpha.com
Apellis Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
May 5, 2022 | markets.businessinsider.com
ABC Boosts EPS Outlook, ADPT Sees 20-26% Revenue Growth, ANAB To Report HARP Data In Q3
May 5, 2022 | americanbankingnews.com
Federico Grossi Sells 2,500 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
May 3, 2022 | americanbankingnews.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Pascal Deschatelets Sells 4,000 Shares
April 21, 2022 | finance.yahoo.com
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
April 11, 2022 | finance.yahoo.com
12 Best US Stocks to Buy Now
April 4, 2022 | finance.yahoo.com
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Previous Symbol
CUSIP
N/A
CIK
1492422
Web
www.apellis.com
Phone
(617) 977-5700
Fax
N/A
Employees
476
Year Founded
N/A

Sales & Book Value

Annual Sales
$66.56 million
Price / Sales
68.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.34 per share
Price / Book
9.93

Profitability

EPS (Most Recent Fiscal Year)
($8.03)
Net Income
$-746.35 million
Net Margins
-866.81%
Pretax Margin
-864.88%
Return on Equity
-607.37%
Return on Assets
-86.27%

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
8.85
Quick Ratio
8.58

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
106,522,000
Free Float
96,402,000
Market Cap
$4.59 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/27/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.47 out of 5 stars

Medical Sector

156th out of 1,424 stocks

Pharmaceutical Preparations Industry

61st out of 681 stocks

Analyst Opinion: 4.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

Is Apellis Pharmaceuticals a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals or view top-rated stocks.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Apellis Pharmaceuticals.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.07. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 607.37% and a negative net margin of 866.81%. During the same quarter in the prior year, the company earned ($2.32) EPS.
View Apellis Pharmaceuticals' earnings history.

What price target have analysts set for APLS?

14 brokers have issued 12 month price objectives for Apellis Pharmaceuticals' shares. Their forecasts range from $28.00 to $102.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $69.64 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 50, Pay $969.54k)
  • Dr. Pascal Deschatelets Ph.D., Co-Founder & Chief Scientific Officer (Age 52, Pay $609.85k)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 48, Pay $578.01k) (LinkedIn Profile)
  • Mr. Alec Machiels J.D., MBA, Co-Founder & Director (Age 49, Pay $72.5k) (LinkedIn Profile)
  • Mr. Timothy E. Sullivan, CFO & Treasurer (Age 51, Pay $630.17k)
  • Mr. Adam J. Townsend, Chief Commercial Officer (Age 45, Pay $602.69k)
  • Ms. Nur Nicholson, Chief Technical Operations Officer
  • Mr. James G. Chopas CPA, VP, Corp. Controller & Chief Accounting Officer (Age 56)
  • Ms. Meredith Kaya, Sr. VP, Investor Relations & Strategic Fin.
  • Mr. David O. Watson, Gen. Counsel (Age 49) (LinkedIn Profile)
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.04%), BlackRock Inc. (5.56%), State Street Corp (2.73%), Jennison Associates LLC (2.54%), Victory Capital Management Inc. (1.24%) and Bellevue Group AG (1.03%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals.

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Victory Capital Management Inc., Candriam Luxembourg S.C.A., SG Americas Securities LLC, Frontier Capital Management Co. LLC, Walleye Capital LLC, Pier Capital LLC, and Integral Health Asset Management LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Alec Machiels, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, and Pascal Deschatelets.
View insider buying and selling activity for Apellis Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Vanguard Group Inc., Bellevue Group AG, Assenagon Asset Management S.A., Maven Securities LTD, Artal Group S.A., State Street Corp, and Prudential Financial Inc..
View insider buying and selling activity for Apellis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $42.35.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals has a market capitalization of $4.51 billion and generates $66.56 million in revenue each year. The company earns $-746.35 million in net income (profit) each year or ($8.03) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 476 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at (617) 977-5700 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.